# OnCo record imc-001 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/imc-001/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "imc-001" ;
  schema:name "IMC-001"@en ;
  schema:alternateName "STI-3031"@en ;
  schema:description "IMC-001 is an experimental monoclonal antibody from ImmuneOncia Therapeutics, in phase 2 trials for extranodal NK/T-cell lymphoma, nasal type, TMB-high solid tumours and resectable gastric, oesophageal and liver cancer."@en ;
  schema:url <https://onco.cc/drugs/imc-001/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.immuneoncia.com/en/m24.php>, <https://www.immuneoncia.com/en/m23.php>, <https://clinicaltrials.gov/api/v2/studies/NCT04414163>, <https://clinicaltrials.gov/search?intr=IMC-001> ;
  onco:status "phase-2" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Monoclonal antibody (fully human IgG1)" ;
  onco:cancers <https://onco.cc/cancers/extranodal-nk-t-cell-lymphoma/>, <https://onco.cc/cancers/metastatic-cancer/>, <https://onco.cc/cancers/hcc/> ;
  onco:targets <https://onco.cc/targets/pdl1/> ;
  onco:companies <https://onco.cc/companies/immuneoncia-therapeutics/> ;
  onco:trials <https://onco.cc/trials/nct04414163/>, <https://onco.cc/trials/nct06365840/>, <https://onco.cc/trials/nct03644056/>, <https://onco.cc/trials/nct04196465/>, <https://onco.cc/trials/nct05393713/> .